ANI Pharmaceuticals Inc (ANIP)
67.25
+0.14
(+0.21%)
USD |
NASDAQ |
May 03, 16:00
67.27
+0.02
(+0.03%)
After-Hours: 20:00
ANI Pharmaceuticals Revenue (Quarterly): 131.65M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 131.65M |
| September 30, 2023 | 131.83M |
| June 30, 2023 | 116.55M |
| March 31, 2023 | 106.79M |
| December 31, 2022 | 94.23M |
| September 30, 2022 | 83.82M |
| June 30, 2022 | 73.86M |
| March 31, 2022 | 64.48M |
| December 31, 2021 | 60.93M |
| September 30, 2021 | 52.06M |
| June 30, 2021 | 48.62M |
| March 31, 2021 | 54.52M |
| December 31, 2020 | 57.25M |
| September 30, 2020 | 52.98M |
| June 30, 2020 | 48.47M |
| March 31, 2020 | 49.77M |
| December 31, 2019 | 47.97M |
| September 30, 2019 | 51.34M |
| June 30, 2019 | 54.36M |
| March 31, 2019 | 52.89M |
| December 31, 2018 | 57.12M |
| September 30, 2018 | 50.70M |
| June 30, 2018 | 47.27M |
| March 31, 2018 | 46.48M |
| December 31, 2017 | 47.29M |
| Date | Value |
|---|---|
| September 30, 2017 | 48.16M |
| June 30, 2017 | 44.76M |
| March 31, 2017 | 36.63M |
| December 31, 2016 | 38.20M |
| September 30, 2016 | 38.52M |
| June 30, 2016 | 31.34M |
| March 31, 2016 | 20.56M |
| December 31, 2015 | 18.04M |
| September 30, 2015 | 19.97M |
| June 30, 2015 | 19.52M |
| March 31, 2015 | 18.80M |
| December 31, 2014 | 21.04M |
| September 30, 2014 | 17.39M |
| June 30, 2014 | 6.647M |
| March 31, 2014 | 10.90M |
| December 31, 2013 | 10.53M |
| September 30, 2013 | 7.836M |
| June 30, 2013 | 6.152M |
| March 31, 2013 | 0.145M |
| December 31, 2012 | 1.968M |
| September 30, 2012 | 0.1104M |
| June 30, 2012 | 0.1088M |
| March 31, 2012 | 0.114M |
| December 31, 2011 | 0.1144M |
| September 30, 2011 | 0.1828M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
47.97M
Minimum
Dec 2019
131.83M
Maximum
Sep 2023
72.71M
Average
57.25M
Median
Dec 2020
Revenue (Quarterly) Benchmarks
| Ligand Pharmaceuticals Inc | 28.10M |
| ADMA Biologics Inc | 73.90M |
| Moderna Inc | 167.00M |
| Dentsply Sirona Inc | 953.00M |
| Allogene Therapeutics Inc | -0.044M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | 1.155M |
| Total Expenses (Quarterly) | 122.94M |
| EPS Diluted (Quarterly) | 0.02 |
| Enterprise Value | 1.506B |
| Gross Profit Margin (Quarterly) | 59.42% |
| Profit Margin (Quarterly) | 0.88% |
| Earnings Yield | 1.22% |
| Operating Earnings Yield | 4.05% |
| Normalized Earnings Yield | 1.362 |